
APstem’s focus remains to fight severe incurable diseases
APstem originated from an innovation of adult mouse peripheral blood-derived stem cells exclusively licensed from Stanford University.
APstem subsequently established human AHPSCs (patented).
AHPSCs have demonstrated significant regenerative ability and safety profile. The therapeutic efficacy of AHPSCs has been proven in a variety of injury or disease animal models, including type I and type II diabetes, chronic wounds (diabetic wounds treatment discussed via pre-IND meeting with the FDA), and central nervous system disease.

The APstem Team
Min Hu MD, PhD
Founder, CEO
and President
Dr. Min Hu has more than 20 years of experience in the fields of stem cell biology, gene therapy and regenerative medicine.
[read more]
Shaowei Li MD
Co-Founder, CSO
and Vice President
Prior to joining APstem Therapeutics, Dr. Shaowei Li conducted stem cell research at Stanford University for well over 10 years.
[read more]
Bowen Liu PhD
Co-Founder, COO
and Director of IP
Before joining APstem Therapeutics, Dr. Bowen Liu was at Sheppard Mullin Richter & Hampton LLP, an AmLaw 100 law firm.
[read more]
Bo (Eric) Liu, MS
Bo (Eric) Liu has over ten years of lab management experience and research experience of in vivo models and studies. Prior to joining APstem Therapeutics, Eric managed and oversaw research labs and vivarium at Stanford University.
Jessica Huang, BS
Jessica is research associate working on preclinical and histological studies.
Alexandra Capela, PhD
Dr. Alexandra Capela has over 14 years of pre-clinical research and industry experience in stem cell therapies and translational projects. She has extensive regulatory expertise on several IND submissions.
Advisory Board
Jane Lebkowski,
PhD
Dr. Lebkowski is an internationally recognized leader in the development of cell and gene-based therapies.
[read more]
Jonathan Lakey,
Ph.D., MSM
Dr. Lakey is a world-renowned diabetes and islet transplantation expert and co-developer of the Edmonton Protocol…
[read more]
Jeffrey L. Cleland, PhD
.
Dr. Cleland has 30 years of industry experience in research and development -
[read more]
Mark S. Kipnes, MD
.
Dr. Kipnes is a diabetes & metabolism endocrinologist. He has over 40 years of clinical experience in diabetes treatment and clinical trials.
[read more]
Alexander Reyzelman, DPM
Dr. Reyzelman is board certified in Podiatric Surgery and Professor at the California School of Podiatric Medicine at Samuel Merritt University.
[read more]
George Michalopoulos,
MD, PhD
Dr. Michalopoulos is a pioneer in the study of molecular pathways involved in liver regeneration.
[read more]
.
Tho Pham, MD
.
Dr. Pham is Clinical Associate Professor at Stanford University and Chief Medical Officer at Stanford Blood Center.
[read more]
Michael Siani-Rose
.
Michael Siani-Rose has over 20 years of experience in the fields of regenerative medicine, biotechnology and bioinformatics.